Boumpas, Dimitrios T.
Sidiropoulos, Prodromos
Settas, Loukas
Szczypa, Piotr
Tsekouras, Vassilis
Hernandez Daly, Ana C.
Funding for this research was provided by:
Pfizer
Article History
Received: 9 February 2018
Accepted: 27 March 2019
First Online: 29 April 2019
Ethics approval and consent to participate
: This study was conducted in accordance with the International Conference on Harmonisation guideline for good clinical practice and the ethical principles of the Declaration of Helsinki. All patients gave written informed consent, which was reviewed and approved by an independent ethics committee or institutional review board. This study (B1801120) was approved by the Greek Regulatory Authorities (approval numbers 85,282 [14 December 2009] and 36,404 [9 June 2010]) and is registered with ClinicalTrials.gov (NCT01001182).
: Patients provided written informed consent for use of their anonymized and aggregated data for research and sharing with other parties.
: D.T. Boumpas has received fees from unrestricted grants deposited to the University Research Account from AbbVie, BMS, Celgene, GSK, MSD, Pfizer, Roche, and UCB. P. Sidiropoulos has received fees from unrestricted grants deposited to the University Research Account from AbbVie, BMS, Celgene, GSK, MSD, Pfizer, Roche, and UCB. L. Settas has received fees from MSD, UCB, Novartis, and Pfizer. P. Szczypa, V. Tsekouras, and A.C. Hernandez Daly are employees of Pfizer.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.